Long noncoding RNAs and Alzheimer's disease

• Main Authors: Luo Q, Chen Y
• Format: Article
• Language: English
• Published: Dove Medical Press 2016-06-01
• Series: Clinical Interventions in Aging
• Subjects: lncRNA; Alzheimer’s disease; ncRNAs; Amyloid β peptide，β-site amyloid precursor protein cleaving enzyme-1
• Online Access: https://www.dovepress.com/long-noncoding-rnas-and-alzheimer39s-disease-peer-reviewed-article-CIA

Qiong Luo,1,2 Yinghui Chen1,2 1Department of Neurology, Jinshan Hospital, 2Department of Neurology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China Abstract: Long noncoding RNAs (lncRNAs) are typically defined as transcripts longer than 200 nucleotides. lncRNAs can regulate gene expression at epigenetic, transcriptional, and posttranscriptional levels. Recent studies have shown that lncRNAs are involved in many neurological diseases such as epilepsy, neurodegenerative conditions, and genetic disorders. Alzheimer’s disease is a neurodegenerative disease, which accounts for >80% of dementia in elderly subjects. In this review, we will highlight recent studies investigating the role of lncRNAs in Alzheimer’s disease and focus on some specific lncRNAs that may underlie Alzheimer’s disease pathophysiology and therefore could be potential therapeutic targets. Keywords: lncRNA, Alzheimer’s disease, ncRNAs, amyloid β peptide, BACE1, BC200, BACE1-AS